SAN DIEGO, June 1, 2026
Resmed has completed its acquisition of Noctrix Health, significantly expanding its clinical sleep health portfolio and strengthening its position in the rapidly evolving field of sleep medicine. The transaction brings Noctrix’s innovative Nidra® Tonic Motor Activation (TOMAC) Therapy into Resmed’s growing ecosystem of connected healthcare technologies. The FDA-cleared, non-invasive, non-pharmacologic therapy is designed to treat moderate-to-severe Restless Legs Syndrome (RLS) in adults who have not achieved sufficient relief through conventional drug treatments. By integrating Noctrix’s clinically validated wearable therapeutic technology with its existing digital health and sleep care platforms, Resmed aims to address a major unmet medical need affecting millions of individuals worldwide. The acquisition represents a strategic milestone in the company’s long-term growth strategy while reinforcing its commitment to delivering innovative solutions that improve sleep quality, patient outcomes, and home-based healthcare management. As sleep disorders continue to emerge as a major public health challenge, the addition of TOMAC Therapy positions Resmed to expand beyond traditional sleep apnea management and enter one of the most underserved areas of sleep medicine.
FDA-Cleared TOMAC Therapy Addresses Significant Unmet Need
Restless Legs Syndrome is recognized as one of the most common sleep-related neurological disorders, affecting a substantial portion of the adult population and frequently leading to chronic sleep disruption, fatigue, and reduced quality of life. Despite the availability of pharmaceutical treatments, many patients continue to experience persistent symptoms or encounter limitations associated with long-term medication use. Noctrix Health’s Nidra® TOMAC Therapy offers a novel alternative through a wearable therapeutic approach that stimulates targeted motor pathways to reduce symptoms and improve sleep quality without the use of drugs.
The therapy has achieved FDA De Novo classification, validating its safety and effectiveness for patients with moderate-to-severe RLS who have not responded adequately to medication. In addition to regulatory clearance, TOMAC Therapy has generated significant clinical evidence through multiple peer-reviewed publications and has been incorporated into the American Academy of Sleep Medicine clinical practice guidelines. These achievements demonstrate growing acceptance within the medical community and underscore the therapy’s potential to transform treatment pathways for patients seeking effective, non-pharmacologic solutions.
Strategic Acquisition Strengthens Resmed’s Sleep Health Ecosystem
Advertisement
The acquisition aligns closely with Resmed’s broader strategy of expanding its leadership across sleep health, respiratory care, and home healthcare technologies. Historically recognized for its innovations in sleep apnea treatment and connected respiratory devices, Resmed has increasingly focused on building a comprehensive portfolio capable of addressing multiple sleep-related disorders. By adding Noctrix Health’s wearable therapeutic platform, the company gains access to a complementary technology that expands its clinical reach into neurological sleep disorders.
Resmed plans to integrate TOMAC Therapy into its network of connected devices, cloud-based digital health platforms, and patient management solutions. This integration could enhance patient engagement, improve care coordination, and create new opportunities for personalized treatment pathways. The acquisition also provides a pathway to scale TOMAC Therapy globally, leveraging Resmed’s commercial infrastructure, provider relationships, and extensive healthcare distribution network to improve access for patients who may benefit from innovative sleep health interventions.
Expanding Innovation Across Connected Care and Sleep Medicine
The completion of the acquisition reflects broader trends shaping the future of healthcare, where wearable therapeutics, digital health platforms, and non-pharmacologic treatment approaches are becoming increasingly important components of patient care. As healthcare systems seek more effective ways to manage chronic conditions while reducing reliance on medications, technologies such as TOMAC Therapy offer a promising alternative. Industry experts anticipate growing demand for clinically validated wearable therapies capable of delivering measurable outcomes while integrating seamlessly into home-based care models.
Through this transaction, Resmed strengthens its ability to provide comprehensive solutions that span diagnosis, treatment, monitoring, and long-term disease management. The combination of Noctrix’s innovative therapeutic technology and Resmed’s expertise in connected healthcare creates new opportunities to advance sleep medicine and improve patient quality of life. As adoption of digital therapeutics and wearable medical technologies accelerates globally, the acquisition positions Resmed at the forefront of a rapidly expanding market focused on personalized, data-driven, and patient-centered healthcare solutions.
Source: Resmed, Noctrix Health press release
